E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Sensorineural hearing loss (SNHL) |
|
E.1.1.1 | Medical condition in easily understood language |
Hearing loss due to damage to the hair cells in the cochlea |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040016 |
E.1.2 | Term | Sensorineural hearing loss |
E.1.2 | System Organ Class | 100000004854 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objectives of this trial (Part B) are: 1. Main objective is to establish the efficacy of local treatment with LY3056480 in terms of hearing at 12 weeks; 2. To establish the efficacy of local treatment with LY3056480 in terms of hearing at 6 weeks; 3. To assess the safety and tolerance of local treatment with LY3056480 |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female between 18 and 80 years of age; 2. A primary complaint of hearing loss of ≤ 20 years in duration, the history suggesting this hearing-loss to be of age-related, noise-induced or idiopathic origin; 3. A bilateral, symmetrical (<15 dBHL difference) SNHL with a pure-tone average threshold across the frequencies 0.5, 1, 2, 4 and 8 kHz of between 25 and 60 dBHL with 2 or more frequencies less than 60 dBHL. |
|
E.4 | Principal exclusion criteria |
1. Presenting with a primary complaint of tinnitus; 2. A ‘true’ air-bone gap ≥15 dBHL in 3 or more contiguous frequencies between 0.5, 1, 2, 4 kHz; 3. History of suspected or diagnosed genetic cause of hearing loss; 4. Suspected or known diagnosis of inner ear pathology, congenital hearing loss, fluctuating hearing loss, Ménière’s disease, or secondary endolymphatic hydrops, perilymph fistula, cochlear barotrauma, autoimmune hearing loss, radiation-induced hearing loss, retro-cochlear lesion; 5. Evidence of acute or chronic otitis media or otitis externa on examination; or a history of middle ear pathology and/or surgery; 6. Any therapy known as ototoxic within 12 months of screening. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcome measure for part B is change in hearing from baseline at week 12 in the treated ear accross three frequencies as measured by pure tone audiometry. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety endpoints will be evaluated from baseline up to week 12. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints for Part B are change from baseline to 6 and 12 weeks in hearing, tinnitus, balance, facial nerve function and taste, and occurrence and severity of local and systemic adverse events related to treatment and/or procedure, and clinically significant changes in ECG, vital signs, physical examination findings and laboratory tests.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 6 and 12 weeks after starting the treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |